Introduction
The biological activities of blood coagulation enzymes are regulated by protease inhibitors of the serpin superfamily, particularly anti-thrombin 111 (ATIII). This protease inhibitor is a 58,000 KD protein that inactivates its target enzymes, such as thrombin, by forming covalent complexes with them. ATIII binds heparin and induces a conformational change in the protein that augments the mode of formation of enzyme-inhibitor complexes by several orders of magnitude (1).
Heparan sulfate proteoglycans (HSPGs) are members of the family of cell surface and extracellular matrix PGs that are either inserted into the cell membrane or localized within the extracellular matrix by complexing with collagen, fibronectin, laminin, and other structural glycoproteins (2-5). Molecular cloning studies have identified distinct core proteins in surface membrane-associated HSPGs: syndecan from epithelial cells, ryudocan from rat endothelial cells, Supported brane. Equally important is the observed variation in expression of ATIII in the various tissues studied (i.e., kidney > liver, aorta, lung, spleen, adrenal >intestine, muscle, brain).
On the basis of these observations, we confirm a model in which vascular abluminal and, perhaps to a much smaller extent, luminal anticoagulantly active HSPGs regulate coagulation mechanism activity, either by serving as a reserve of anticoagulant or by modulating the ambient function of the coagulation cascade. (JEiistochem C y " 4213654376, KEY WORDS: Anti-thrombin 111; Cryoultramicrotomy; Immunocytochemistry; Electron microscopy; Heparan sulfate proteolgycans; Anticoagulation; Rat vasculature.
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fibroglycan and glypican from fibroblasts, and perlecan associated with basement membranes (6-10). HSPGs secreted with no hydrophobic domains may be relatively resistant to the action of pronase and may accumulate predominantly in the basement membrane (llJ2).
The hypothesis that the non-thrombogenic properties of blood vessels are related to anticoagulantly active heparin-like components associated with endothelial cells (13) is supported by several independent lines of evidence. HSPGs with heparin-like activity have been extracted from bovine microvascular capillary endothelial cells and from aortic endothelium (14J5). Cultured cloned or non-cloned bovine macrovascular endothelial cells and rodent microvascular endothelial cells synthesize a unique subset of anticoagulantly active HSPGs (1-10% of total HSPGs) containing appropriate monosaccharide sequences to bind and activate ATIII (8, 9, 16, 17) . ATIII interacts with anticoagulantly active HSPGs on freshly prepared bovine aortic segments with endothelial cells intact, and the complexed protease inhibitor rapidly neutralizes added coagulation enzymes (18). The perfusion of intact rat or mouse hindlimb vasculature with purified thrombin as well as ATIII leads to a 20-fold enhanced rate of formation of coagulation enzyme-protease inhibitor com-plexes. This acceleratory phenomenon is caused by anticoagulantly active HSPGs. since the effect can be eliminated by prior infusion with purified Flavobacterium heparinase (17.19). Recent reports indicate that a small percentage of endothelial cell HSPGs are linked with anticoagulantly active heparan sulfate chains, whereas the bulk of core proteins are linked to anticoagulantly inactive heparan SUIfate chains (8,9). It is to the former, anticoagulantly active HSPGs, that ATIII is reported to bind at a specific site (8) .
ATIII infused into rabbits and humans distributes into three compartments: plasma, the vessel wall, and an extravascular compartment (20,21). Both intact and de-endothelialized rabbit aorta segments have been used to study ATIII binding to the vascular endothelium and to the subendothelial basement membrane (22). Flavobacterium heparitinase treatment of the exposed subendothelium reduced the ATIII binding and also seemed to deplete the subendothelium of small PG-rich granules and basement membrane (23). Transmission electron microscopic autoradiographs of [ '2sI]-ATIII-perfused arteries showed binding to the subendothelium (24). The HSPG-ATIII anticoagulant pathway in human kidney tissue has been examined by immunofluorescence LM, which has confirmed the association of ATIII with vascular surfaces (25.21).
In this study we visualized the position and relative quantity of endogenous ATIII binding sites in the subendothelial spaces of microvasculature of a large number of different rat tissues by immunocytochemistry. This binding site is inferred to be HSPG (8.9.24). These data expand our earlier data from autoradiographic experiments in which ATIII was added by vascular perfusion (24) and suggest that substantial quantities of ATIII are associated with the vascular basement membrane and extracellular matrix components, supporting the hypothesis that anticoagulantly active HSPG is involved in regulating coagulation system activity.
Materials and Methods
Animals. Male Sprague-Dawley rats weighing 300-400 g were anesthetized by peritoneal injection of an overdose of pentobarbital (80 mglkg body weight). For LM immunocytochemistry, various tissues and organs were removed. embedded in OCT compound (Miles; Elkhart. IN). quenched in dry ice-cooled isopentane. and stored at -7O'C until use. For immunoelectron microscopy, the animals were perfused through the I& ventricle with 0.001% glutaraldehyde and 2% paraformaldehyde in 0.1 M phosphate buffer. pH 7.4, for about 15 min at a constant pressure of 100 mmHg. The tissues were then removed, chopped into small cubes, and I& for another 45 min in fixatives with various concentrations (0.001-0.1%) of glutaraldehyde in Zamboni fixative (27) to achieve satisfactory ultrastructure, adequate labeling intensity. and lowest background. The cubes were then infused overnight with 2.3 M sucrox at 4'C. quick-frozen, and stored in liquid nitrogen until use. Animals were handled in accordance with our institution's guidelines for use and care of laboratory animals.
Reagents and Antibodies. Purified human ATIII was purchased from Cutter Biological (Berkeley. CA). Heparinase I was obtained from R.D. Rosenberg and Sigma (St Louis, MO). Rabbit anti-human ATIII IgG was purchased from Dakopatts (Glostrup, Denmark). Peroxidase-conjugated donkey anti-rabbit IgG. colloid gold-conjugated goat anti-rabbit IgG, and silver enhancement kit (IntcnscM) were purchased from Amenham (Arlington Heights. IL). 3-Amino-9-ethyl carbazole (AEC) was obtained from Sigma. in sample buffer containing 0.062 M Tris-HCI (pH 6.8). 5% SDS, 10%
SDS-PAGE and
glycerol. 4 M urea, 0.001% bromophenol blue with 5% dithiothrcitol (DTT). An estimated 0.25 mg of cryostat section protein was loaded in each well. Purified ATIII 2 pg was loaded in the control lane. Samples were incubated for 10 min at 80°C before loading. SDS-PAGE was performed with a 4% stacking gel (28). Electrophoresis was performed on 10% acrylamide. Molecular weight calibrations were made using serum albumin, and IgG. Electroblotting was performed essentially as described elsewhere (29). using a sandwich of gel and pH 7.9 0.1 nitrocellulose (Schleicher & Schuell; Keene. NH). Electroblots blocked with "Blotto" solution (30) were treated with specific anti-ATIII IgG. washed with blot wash buffer (0.05 M phosphate. saline with 0.1% Twcen 20). and antigen recognition performed by incubating blots with a secondary goat anti-rabbit IgG-horseradish peroxidase conjugate and subsequently with chemiluminescence solution (31). as described by the manufacturer (Amersham) or by the amino ethyl carbazole (AEC) method (32).
Dot-Blot Assay. Samples of solubilized tissue or purified ATIII were spotted onto nitrocellulose to give a range of 10 ng to 2 pg ATIII per dot. This procedure was sensitive to as little as 0.2 ng ATIII antigen. The dots were air-dried and the sheets blocked with Blotto solution before incubation with 40 ml of primary antibody at -50 pglml at 4'C for 4 hr. The blots were washed and spots revealed with AEC and inspected for relative intensity. Values were normalized per gram of original tissue. lmmunofluorexpnce and Immunogold-Silver Staining on Cryostat Sections. Frozen sections 6 pm thick were made with an Ames Cryostat I1 (Miles) and were placed on poly-L-lysine-coated slides. They were quickly air-dried and fixed at room temperature (RT) in absolute acetone for 10 min. After blocking with 1% ovalbumin for 30 min, the sections were incubated with rabbit anti-human ATIII (150) for 45 min at 37'C. The slides were then washed with PBS and incubated either with FIE-goat anti-rabbit IgG for immunofluorescence (IF) or with colloid gold-goat anti-rabbit IgG for immunogold silver staining (IGSS) for 30 min at 37°C. Sections stained by IF were mounted with buffered glycerol and examined with a Zeiss photomicroscope 111. Sections stained by IGSS were incubated for about 20 min with silver enhancement solution and examined by transmitted light using the same microscope.
lmmunwlectron Microscopy on Ultra-thin Cryosections. Ultra-thin frozen sections (80-110 nm thick) were cut on dry glass knives with a Reichert Ultracut E ultramicrotome fitted with a cryochamber operating at -100 to -120°C. The sections were lifted in a small droplet of 2.3 M sucrose solution and placed on Formvar-carbon-coated copper grids (75 mesh). The sugar solution was then removed by three washes with PBS and the sections were washed three times with PBS containing 0.5% bovine serum albumin (BSA) and 0.15% glycine, pH 7.4 (Buffer A). This was followed by a 30min incubation with 1% egg albumin in PBS at RT. Sections were then incubated for 30 min with the primary antibody (1-2 pglml), and secondary antibody gold-conjugates of 10-or 15-nm gold particle size (10 pg/ml).
The sections were washed six times (5 min/wash) with Buffer A and were stained twice with uranyl acetate, once for 2 min in 1% neutral uranyl acetate and then with 4% unbuffered uranyl acetate for 2 min (33). and mounted in a thin film of 1.25 T o methylcellulose (Fluka; Ronkonkoma NY), allowed to dry, and examined at 80 kV with a JEOL 100-CX transmission electron microscope at a magnification of x 10.000-40,000, For the aorta, quantitation of specific uptake of immunogold signal was performed by counting the number of immunogold particles per unit area in well-defined zones of the aortic wall, i.e., intima, including subendothelial space, and media. Gold particles on cell cytoplasm and nuclei as well as those on luminal open space were used for comparison as background. Student's t-test was used to test the significance of differences in immunolabeling intensity on various zones of the aortic wall.
Negative Controls for Immunostaining. To ascertain that immunostaining with rabbit anti-human ATIII at both LM and EM level was specific for the rat antigen, several negative controls were employed pre-absorption of antibody with an excess of pure ATIII; omission of the primary antibody; replacement of the primary antibody with irrelevant antibody of the same isotype; and pre-treatment of the sections with heparinase, in which case the sections were digested with heparinase I in 50 mM Tris, 5 mM CaC12, 0.5 mglml BSA. both with and without 1 mM PMSF, pH 7.0 (28), at 0.5 U/ml for 30 min at 37°C for ultra-thin cryosections or at 20 Uiml for 1 hr for cryostat sections before washing and the application of antibody.
Results
To show that our primary antibody directed against human ATIII detected rat ATIII antigen, and to show that biochemically detectable quantities were present, Western blots of control purified ATIII were compared with those of rat kidney and liver tissue dissolved in SDS (Figure 1 ). A single intense band was formed in both tissue extracts at the same position as the main band in the ATIII control. From a series of lanes loaded with various quantities of ATIII, comparisons with various known amounts of tissue, loaded both on SDS-PAGE immunoblots and on dot-blots, permitted the estimation of mg ATIII per gram of tissue in the range of 1 to 20, where liver was 1-5 mg/lOO g of tissue and kidney was 20 mg/100 g.
Light Microscopic Localization of ATIII on Cryostat Sections
At the LM level, arteries and veins of different sizes all showed variable positive staining for ATIII on the lining of the lumen in all tissues examined, including aorta, kidney, liver, lung, brain, spleen, myocardium, skeletal muscle, intestine, and adrenal gland. The signal was monitored as a linear fluorescence or silver deposit along the lining of the vascular lumen. The intensity of staining, however, varied with the size of the vasculature. In the aorta and other larger vessels, which usually showed stronger staining, the positive staining presented as a continuous line delineating the lumen of the vessels (Figures 2A and 2B ). In Figure 2A , fluorescent staining of the wall of an aorta is continuous but variable in intensity (arrows on the luminal side). The staining pattern and intensity of arteries and veins seemed to be similar for equivalent diameters. In Figure 2B a medium-sized kidney artery shows a convoluted fluorescence staining pattem, similar in intensity to that shown in Figure 2C for a vein in the cardiac atrium. The weak staining pattern in smaller arteries is illustrated in Figure 2D .
Capillaries were also positively stained for ATIII in kidney, liver, spleen, lung, and adrenal gland. In general, the kidney showed strong positive staining along the walls of capillaries between the renal tubules. In the glomeruli, the vascular loops were also positively stained. Figure 3A shows positive staining in kidney with IGSS along the capillary wall between the renal tubules (highlighted arrows) and vascular loops in the glomeruli (arrows marked G). Figure 3B shows a high-magnification micrograph of the glomerulus with a distinct staining pattern of the capillary basement membrane. The mesangial matrix also appeared to be stained. In the liver, the portal vasculature, including portal veins, portal arteries, subloburar veins, and terminal hepatic venules, was positively stained. Within the lobules the staining was along the sinusoidal lining and appeared stronger in the mid-zone of the lobules (Figure 3C) . In the spleen, the central artery within the white pulp showed strong staining. Figure 3D illustrates specific immunofluorescence staining for ATIII around splenic capillaries (arrows) in the white pulp area. However, parallel immunostaining in other tissues, including intestine, myocardium, and brain, did not show clear positive staining in capillary structures. This is illustrated in Figure 4A , which shows absence of immunofluorescence staining for ATIII around jejunal capillaries within an intestinal villus (arrows). The sinusoids in the adrenal cortex showed positive staining, with a staining pattern remarkably similar to that seen in the liver (data not shown). Since definitive association with either the luminal or the basal surface of the vascular endothelium was not possible owing to the limited resolution of LM, electron microscopy was undertaken.
Electron Microscopic Localization of ATIII by Immunogold Staining on Ultra-thin Frozen Sections.
At the EM level, positive labeling for ATIII could be clearly resolved and was observed primarily in the vascular subendothelial space. In the aorta and other larger vessels, the immunogold was localized in the area between endothelial cells and the elastica interna. It seemed to be associated with the basal lamina and some amor- phous connective tissue components, and not particularly with the elastic or collagen fibrils. Very few gold particles were localized on the luminal cell membrane of the endothelium ( Figure SA) . Components present in the media and adventitia of the large vessels showed no labeling above background. Quantitative analysis of immunolabeling on the aorta sections showed that the subendothelial space contained 29.2 x lo8 gold particles/cm2 (in real space), 8.1 x lo8 particles/cm2 in the luminal surface zone (defined as a 40nm zone next to the endothelial surface), and 3.6 x lo8 particles/cm2 in the media compared with a background level of 3.2 x lo8 particles/cm2. The difference in intensity was significant between media and subendothelial space @<0.05) and between subendothelial space and background @<0.05), whereas the counts in media or in the luminal surface zone did not differ significantly from that of the background @<0.25). This strongly supports the subendothelial space as the principal site at which over 99% of ATIII is concentrated in the aortic wall. Again, heparinase treatment abrogated staining for ATIII.
In the kidney, the capillaries between the renal tubules showed strong labeling in the subendothelial space, with gold particles localized just underneath the endothelial cells (Figure 5B , arrowheads) and clearly clustered in association with the vascular basement membrane ( Figure 5B, arrows) . As many as 20 gold markers were concentrated on some approximately round electron-dense structures averaging about 0.15 pm in diameter (arrows in Figures 5B and  5C) , found spaced within the basement membrane with a typical spacing distance of about 0.3-0.5 vm (arrows, Figures 5B and 5C ). In the subendothelial space, underneath the main cell body, a labeling pattern was noted similar to subendothelial regions beneath the thin cytoplasmic layer, where fenestrations were often found ( Figure 5C ). Labeling intensity was also strong in electron-dense loci within regions of tangential sections of the vascular basement membrane (Figure 5B) . The large, periodic collagen fibrils in the subendothelial space and the basement membrane of the renal tubules were usually unstained. In the glomeruli, labeling of the subendothelium showed similar patterns but weaker reaction, with gold label present between the basal surface of the endothelial cell membrane and the glomerular basement membrane (5C, inset). There was also weak labeling on some amorphous materials associated with the surfaces of mesangial cells (data not shown). In the lungs, ATIII labeling was irregularly scattered on the vascular basement membrane ( Figure 6A ) and was also associated with some amorphous extracellular connective tissue components between the vessels within the septae. In the spleen, labeling was also present in the subendothelial space of the capillaries found in the white pulp associated with non-fibrillar components (Figure 6B) . Basement membrane was present in the splenic capillaries but was less distinct than in kidney. In the adrenal cortex, positive labeling often occurred along collapsed sinusoids. Gold markers were associated with the interdigitating cytoplasmic processes of adrenal vascular endothelial cells generally, but typical basement membrane was not well identified in these areas in frozen sections ( Figure 6C ).
All negative controls (e.g., pre-absorption of antibody, with antigen, omission or replacement of primary antibody) resulted in definite negative staining (Figure 4D) . Pre-treatment of sections with heparinase in buffer with or without the protease inhibitor PMSF completely abrogated the positive staining in kidney tissue that produced the strongest positive staining withcut heparinase (Figure 4B, undigested; Figure 4C , digested). Table 1 summarizes the data for the tissues examined by both light and electron microscopy.
Discussion
In the present study we have confirmed by immunocytochemistry the locus of ATIII in the vasculature at a resolution far greater than previously reported. Particularly interesting is the finding that the amount of ATIII detected in the capillaries varied greatly from one tissue to another. ATIII, and by inference ATIII-HSPG complex, is present selectively in sinusoids and fenestrated vessels, where the vascular basement membrane is more likely to come into contact with contents of the lumen, whereas it is attenuated in continuous capillaries, such as those found in brain and skeletal muscle. The locus in kidney is primarily in discrete electron-dense regions of the subendothelial basement membrane. These may be identical to electron-dense masses found in standard plastic sections of this region (unpublished data), and labeled by cationic ferritin for HSPG (34-36) physically subjacent to endothelial cell fenestrae. We thus confirm a model in which vascular abluminal anticoagulantly active HSPG regulates coagulation mechanism activity by providing a reserve of anticoagulant or, by interacting with ATIII in modulating the function of the coagulation cascade. The value of EM localization of HSPG will be important in elucidating the various possible functions of HSPG.
Although the function of HSPG complexes is not fully understood, it is thought that they may function in cell growth (37,38), cell attachment (39), differentiation (40), cell-cell interaction (41), cell-substrate interaction (42,43), regulation and manifestation of immune responses (44), and in anticoagulation (13). It is now established that basement membrane contains heparan sulfate (34-36,42,45-49) and that perlecan is a principal basement membrane HSPG (50,51).
In the involvement of HSPGs in anticoagulation, anticoagulantly active HSPG chains interact with ATIII regulating the coagulation system by means of this interaction (13). Kojima et al. (8,9) reported that anticoagulantly active HSPGs contain about nine glucuronosyl 3-0-sulfated glucosamines per chain, whereas anticoagulantly inactive HSPGs contain only about three glucuronosyl 3-0-sulfated glucosamines per chain. Immunocytochemical studies have shown that ATIII is associated with the blood vessels in various human tissues (52, 53) . Normally functioning renal allografts manifested the endothelial ATIII-heparan sulfate pathway but, conversely, rejecting or rejected renal allografts showed either a compromised or absent pathway with the diminishment of endothelial ATIII and presence of fibrin deposition (25,26). However, the exact location and nature of the ATIII-heparan sulfate interaction site has not been resolved.
We have previously found that radiolabeled ATIII bound specifically to the HSPG with Ka of ~5 0 nM. The anticoagulantly active HSPGs were found concentrated immediately beneath the aortic and vasa vasorum endothelium, with only a very small amount of labeling detected (estimated at <I%) on the luminal surface of the endothelial cells (24). These previous results prompted us to visualize directly the location of endogenous ATIII binding to blood vessel walls in a number of different tissues by LM and EM immunocytochemistry. In this more direct approach, the sites at which endogenous ATIII, presumably bound to HSPG, was concentrated would be immunogold-labeled at a resolution of about 10-20 nm. Binding sites of ATIII on anticoagulantly active HSPGs were largely concentrated immediately beneath the vascular endothelium in rat aorta and other blood vessels, with only a minimal amount of labeling (estimated at 0.3% of the total detected in a cross-section of the artery) on luminal surfaces of the endothelial cells. In the kidney, gold markers were concentrated in clusters clearly associated with certain electron-dense structures approximately 0.15 pm in diameter, spaced at irregular intervals along the capillary basement membrane, but not the renal tubule basement membrane. The nature of these positively stained structures is unclear, but they appear to be related to the distribution of HSPG in the vascular basement membrane. The irregular spacing of concentrated HSPG-ATIII complexes may also correspond to fenestrations in the covering endothelial cells, although foci also exist in areas apparently devoid of fenestration.
These findings establish that ATIII is associated with the basement membrane on specific microanatomic loci (particularly in kidney). These are identified as enriched in ATIII, removable with heparinase, and presumably attached to HSPGs. This scenario is reminiscent of an earlier report that HSPGs are concentrated near the fenestral diaphragms of the vascular endothelium (54) . Endogenous ATIII does not appear to prevent action of heparinase on proteoglycans, since ATIII labeling is removed by the enzyme. Because perlecan is reported to be the principal HSPG present in basement membrane, it seems very likely that the anticoagulantly active material located in this report by virtue of its ATIII attachment (6,50,55) is, in fact, perlecan. However, it has also been reported that glypican undergoes interaction with ATIII (56) . Therefore, another HSPG species revealed in the connective tissue layer of the blood vessel by ATIII immunogenicity may be glypican, suggesting variation in relative concentrations of different HSPGs found in different ultrastructural compartments. A recent report shows that antibody directed against heparan sulfate itself inhibits its binding to ATIII, decelerates the formation of thrombin-AT111 complexes, and thus inhibits anticoagulation (57) .
In this study we analyzed larger vessels, including aorta, as well as medium and small arteries and veins from a variety of tissues, and in most instances these showed consistently positive staining on the endothelial basement membrane lining. The staining in the capillaries, although uniform in a given tissue, varied greatly in intensity from one tissue to another. Tissues that showed strong staining included kidney, liver, spleen, and adrenal glands, whereas other tissues, including brain and muscle, were not well labeled by the same procedure. The reasons for these variations are unknown but may be related to the physiological significance or activity of capillaries within different tissues and organs involved. For example, it is well known that capillaries in muscle and brain belong to the continuous type, in which the endothelial tube is supported externally by a thin continuous basement membrane. On the other hand, capillaries in the kidney are heavily fenestrated. The capillaries in the liver, spleen, and adrenal glands are considered sinusoids, which are very thin-walled vascular channels usually exhibiting discontinuous or absent basement membranes. One of the most important concerns in the function of capillaries relates to the mechanism of exchange of substances across their walls, i.e., capillary permeability. In the brain, the paucity of transport vesicles and the presence of occluding junctions between endothelial cells appear to account for their lower permeability, resulting in the so-called blood-brain barrier. A lower rate of exchange takes place in these regions, so that there is consequently a smaller chance of thrombosis occurring. This could be related to the low level of ATIII staining that we observed in these tissues. In fenestrated capillaries, however, exchange may be facilitated by the presence of the fenestrae as well as by the poorly developed basement membrane. The probability of developing microthrombosis is greatly increased by frequent contact of blood components with tissue components outside the vessel wall, so that the presence of a high concentration of ATIII in these regions may be of great importance in maintaining homeostasis with respect to coagulation.
The results suggest a scenario in which overlying endothelial cells produce anticoagulantly active HSPGs, initially positioned within the cell membranes by way of their hydrophobic domains, whose protein cores are cleaved by plasmalemma1 proteases, permitting the liberated macromolecules to accumulate within the extracellular matrix. Alternatively, it can be hypothesized that endothelial cells synthesize a class of secretory anticoagulantly active HSPGs that accumulate predominantly in the basement membrane. The two models are consistent with the known synthesis of anticoagulantly active HSPGs by cultured endothelial cells and anticoagulantly inactive HSPGs by cultured smooth muscle cells by in situ hybridization (6), as well as with the previously reported isolation of anticoagulantly active HSPGs from aortic intima and anticoagulantly inactive HSPGs from aortic media (15).
Based on the above discussion, two possible mechanisms by which anticoagulantly active HSPGs might regulate coagulation in vivo are indicated. In the first, small amounts of luminal anticoagulantly active HSPGs would be in position to bind plasma ATIII and accelerate its action. Homeostatic activity would thus be regulated at the blood-vessel wall interface, and the much larger stores of abluminal anticoagulantly active HSPGs would serve as a reserve that would be exposed by extensive trauma. In the second mechanism, substantial amounts of anticoagulantly active HSPGs, accumulated at the abluminal surface of endothelial cells, could modu-late the ambient function of the coagulation cascade. A number of studies that document the extraordinary permeability of the endothelial cell layer (58) suggest that plasma AT111 has ready access to this region. The presence of this subendothelial concentration of anticoagulantly active HSPGs would also explain kinetic radiotracer studies suggesting that a significant amount of labeled protease inhibitor is located in some unique extravascular compartment (16), which is consistent with our findings. Interaction of coagulation enzymes with ATIII bound to subendothelial anticoagulantly active HSPGs could constitute the heparin-like, macromolecule-dependent acceleration of protease inhibitor action observed in animal models referred to above. All of this implies that inhibition of coagulation enzymes is active within subendothelial regions, and expands our present concepts of what constitute critical biological surfaces involved with the homeostatic mechanism.
